Kymera Therapeutics announces 2023 objectives

The Company’s recent data, generated in healthy volunteers and patients with HS, AD, hematological malignancies and solid tumors, demonstrated its industry leading, proprietary know-how in TPD and its progress in developing medicines in areas of significant patient and commercial opportunity. In January, the Company outlined its strategic objectives for 2023: Collaborate with Sanofi to initiate KT-474 Phase 2 clinical trial; Publish results of KT-474 Phase 1 trial including patient cohorts; Demonstrate clinical anti-tumor activity in target patient populations for KT-333 and KT-413; Initiate KT-253 Phase 1 trial in solid and hematological tumors and demonstrate clinical proof-of-mechanism in patients; Deliver at least 2 new development candidates ; Investigational New Drugs from the preclinical pipeline in areas of large clinical and commercial opportunity and pathways where TPD has potential to provide either the only or the best-in-class solution; Further expand the capabilities of Kymera’s Pegasus platform and continue to leverage Kymera’s E3 Ligase Whole-Body Atlas of over 600 unique E3 ligases, with a focus on tissue restricted E3 ligases; Expand novel molecular glue franchise in areas of unmet medical need, exploiting a newly identified degron motif; Advance existing collaborations, or execute additional strategic partnerships, that support the company’s evolution into a fully integrated, global biopharmaceutical company